Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q16288
UPID:
NTRK3_HUMAN
Alternative names:
GP145-TrkC; Neurotrophic tyrosine kinase receptor type 3; TrkC tyrosine kinase
Alternative UPACC:
Q16288; B7Z4C5; E9PG56; H0YND1; O75682; Q12827; Q16289
Background:
The NT-3 growth factor receptor, also known as Neurotrophic tyrosine kinase receptor type 3 or TrkC tyrosine kinase, plays a pivotal role in the development of the nervous system and possibly the heart. It functions by binding to its ligand NTF3/neurotrophin-3, leading to autophosphorylation and activation of signaling pathways such as phosphatidylinositol 3-kinase/AKT and MAPK, which are crucial for cell survival and differentiation.
Therapeutic significance:
Understanding the role of NT-3 growth factor receptor could open doors to potential therapeutic strategies.